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Abstract: The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immuno-
histochemistry (IHC) markers. The objective of this current project was to study the molecular classification of commonly used breast 
cancer cell lines by IHC analysis. Seventeen breast cancer cell lines were harvested, fixed in formalin and made into cell blocks. IHC 
analyses were performed on each cell block with antibodies to estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, CK5/6, 
Ki-67 and androgen receptor (AR). Among the 17 cell lines, MCF-7 and ZR-75-1 fell to Luminal A subtype; BT-474 to Luminal B 
subtype; SKBR-3, MDA-MD-435 and AU 565 to HER2 over-expression subtype; MDA-MB-231, MCF-12A, HBL 101, HS 598 T, 
MCF-10A, MCF-10F, BT-20, 468 and BT-483 to basal subtype. MDA-MB-453 belonged to Unclassified subtype. Since each subtype 
defined by this IHC-based molecular classification does show a distinct clinical outcome, attention should be paid when choosing a cell 
line for any study.
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Introduction
Breast cancer encompasses a group of very hetero-
geneous diseases, which can be demonstrated at the 
molecular, histopathologic and clinical levels.1 The 
heterogeneity at the molecular level has been dem-
onstrated by reproducible differences in the frequen-
cies and magnitudes of genomic aberrations and by 
differential  gene  expression  among  breast  carcino-
mas, even those with similar histology.2,3 Studies on 
whole-genome  analysis  using  expression  microar-
ray have revolutionized our understanding of breast 
carcinomas,  which  has  led  to  the  discovery  of  5 
distinct subtypes of breast carcinomas (Luminal A, 
Luminal B, HER2 over-expression, Basal-like, Nor-
mal-like), each with unique recognizable phenotypes 
and  clinical  outcomes.4–8  Subsequent  studies  have 
shown  that  breast  carcinomas  can  also  be  divided 
into 5 similar subgroups using immunohistochemical 
(IHC) analysis as a surrogate with a limited panel of 
antibody markers (including ER, PR, HER2, CK5/6 
and EGFR).9,10 These subgroups have distinguishing 
features closely associated with subtypes defined by 
gene expression profiling, including distinct clinical 
outcomes,  different  responses  to  adjuvant  therapy 
and  different  patterns  of  metastatic  recurrence.11–14 
Although molecular classification has been mainly 
used in clinical and translational research, many have 
suggested it may have utility in routine clinical prac-
tice in guiding individualized management for breast 
cancer patients.15–17
Breast  cancer  cell  lines  have  been  used  exten-
sively in basic research and have provided valuable 
insight into many aspects of breast cancer biology. 
Cell lines are one of the most critical components in 
studying tumor carcinogenesis,18,19 signal transduc-
tion  pathways,20,21  and  new  therapeutic  targets  for 
breast carcinoma.22–24 However, a cell line chosen for 
a particular study is largely based on its unique bio-
logic features and its availability, and often its ER, 
PR and HER2 status may not be known. If breast 
cancer represents a heterogeneous group of diseases, 
then cell lines derived from different patient’s tumors 
should reflect this biologic diversity. The objective 
of the current project is to investigate the expression 
patterns of the clinically most critical molecules for 
breast cancer (ER, PR HER2, Ki-67, CK5/6, EGFR 
and  AR)14  by  immunohistochemical  (IHC)  analy-
sis  in  17    commonly  used  cell  lines  and  with  this 
  information  determine  the  molecular  classification 
of each cell line.
Methods
Seventeen commonly used breast cancer cell lines 
(MDA-MB-231, SKBR-3, MDA-MB-231-UR, MCF- 
12A,  HBL101,  MDA-MD-435,  MCF-7,  HS598T, 
MCF-10A, BT-20, MCF10F, 468, AU 565, ZR-75-1, 
BT-483, BT-474, and MDA-MB-453) were cultured 
in appropriate medium (Table 2), harvested by cell 
scraper  before  reaching  confluence,  washed  twice 
with PBS, and frozen as cell pellets at −80 °C. Once 
all cell lines were ready, they were thawed on ice, 
and fixed in 10% formalin for 16 hours. Each cell line 
was pelleted and made into a cell block. One H & E 
stain and 7 IHC stains were subsequently performed 
for each cell line. Pretreatments consisted of enzyme 
digestion, or other heat mediated retrieval methods. 
Sections were stained on a Dako Autostainer using 
either a Envision Plus—HRP polymer (Dako, Carpen-
teria, Ca.) or Horse Anti-Mouse IgG-Biotin (Vector 
Laboratories, Inc. Burlingame, Ca), Streptavidin-HRP 
(Jackson Labs) and AEC (Dako, Carpenteria, Ca.), 
and  counterstained  in  hematoxylin.  ER  (clones 
1D5  and  ER-2-123,  Dako),  PR  (clone  PgR  1294, 
Dako) and AR (clone AR441, Dako) were recorded 
as   Allred  scores;25  HER2  (HercepTest,  Dako)  was 
scored as positive if >30% of tumor cells showed 3+ 
membrane staining;26 EGFR (EGFR pharmDx, Dako) 
was designated as positive if any tumor cells showed 
1+ positive stain; any strong cytoplasmic stain was 
considered as positive for CK5/6 (clone D5/16 B4, 
Dako); and Ki-67 (clone MIB-1, Dako) was scored 
as % of any intensity nuclear stain. The definition for 
each molecular subtype was based on the expression 
of ER, PR, HER2, EGFR and CK5/6 as previously 
described17 (Table 1).
Results (Table 3 and Figs. 1 and 2)
Using  the  same  antibodies,  the  same  experimental 
conditions, and the same scoring systems that we use 
for our clinical specimens, we found that two cell lines 
MCF-7 and ZR-75-I were positive for ER; and three 
cell lines MCF-7, ZR-75-I and BT-474 were positive 
for PR. HER2 was found over-expressed in four cell 
lines. Of these four, SKBR-3, MDA-MD-435, and 
AU 565 were ER and PR negative, and BT-474 was 
ER negative and PR positive.Molecular classification of breast cancer cell lines
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Table 1. Definition of each subtype in molecular classification.
eR and/or  
pR
HeR2 
over-expression
eGFR 
and/or 
cK5/6
Luminal A  
subtype
+ − − or +
Luminal B  
subtype
+ + − or +
heR2 subtype − + − or +
Basal like  
subtype
− − +
Unclassified 
subtype
− − −
Table 2. The results of ihC analysis for all breast caner cell lines.
source  culture conditions
MDA-MB-231 ATCC DMeM/F12 with 10% fetal bovine serum
sKBR-3 ATCC The same as MDA-MB-231
MDA-MB-231-UR Dr. guise TA DMeM with 10% fetal bovine serum
MCF-12A ATCC 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F12 medium, 
20 ng/ml human epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml   
bovine insulin, 500 ng/ml hydrocortisone and 5% horse serum
hBL101 ATCC The same as MDA-MB-231
MDA-MD-435 ATCC The same as MDA-MB-231
MCF-7 ATCC The same as MDA-MB-231
hs598T ATCC The same as MDA-MB-231
MCF-10A ATCC The same as MCF-12A
BT-20 ATCC The same as MDA-MB-231
MCF-10F ATCC The same as MCF-12A
468 ATCC The same as MDA-MB-231
AU 565 ATCC The same as MDA-MB-231
ZR-75-1 ATCC The same as MDA-MB-231
BT-483 ATCC The same as MDA-MB-231
BT-474 ATCC The same as MDA-MB-231
MDA-MB-453 ATCC The same as MDA-MB-231
MCF-7 and ZR-75-1 fell within the Luminal A 
subtype; and BT-474 belonged to Luminal B subtype, 
which was repeatedly shown to be ER negative, PR 
positive, HER2 positive, CK5/6 negative and EGFR 
positive. Three cell lines (SKBR,-3, MDA-MD-435 
and AU 565) fell within the HER2 over-expression 
subtype.  Ten  cell  lines  (MDA-MB-231,  MDA-
MB-231-UR, MCF-12A, HBL101, HS598T, MCF-
10A, BT-20, MCF-10F, 468 and BT-483) belonged 
to   Basal-like subtype due to their negativity for ER, 
PR  and  HER2  and  positive  for  EGFR  (10/10  cell 
lines) and/or CK5/6 (3/10 cell lines). MDA-MB-453 
belonged to triple negative non-basal (Unclassified) 
subtype. Only three cell lines (MCF-12A, MCF-10A 
and MCF-10F) were positive for CK5/6. Of these, all 
belonged to Basal subtype. All but 2 cell lines were 
positive for EGFR; one (MDA-MD-435) belonged 
to  HER2  subtype,  and  the  other  (MDA-MB-453) 
belonged to Unclassified subtype.
We found most of the cell lines expressed very high 
levels of Ki-67, ranging from 20% to 100%. MDA-
MB-231  had  100%  positive  stain  for  Ki-67.  Two 
cell lines expressed Ki-67 under 50%, SKBR-3 was 
20% and MCF-10A was 30%. AR was expressed in 
14/17 cell lines, and the three AR negative cell lines 
(HS598T, MCF-10F, MCF-10A) were also negative 
for ER and belonged to basal-like subtype.
Discussion
There  are  many  breast  cancer  cell  lines  available 
and used in various studies. Like primary breast car-
cinomas, these cell lines can be very different from 
one to another.27,28 Although breast cancer cell lines 
have always been a critical tool for most of the basic 
research, they are rarely studied with methods similar 
to those that are used for a routine clinical work up 
for primary breast cancer, such as IHC.
We  were  surprised  to  see  that  only  a  few  cell 
lines  express  ER  (MCF-7  and  ZR-75-1)  and  PR 
(MCF-7, ZR-75-1, and BT-474) with IHC   analysis subik et al
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that  is    routinely  used  for  primary  breast  cancer. 
BT-483, a cell line which was reportedly positive for 
ER,29 failed to showed a positive ER staining in our 
study. One explanation for this could be the differ-
ent   experimental methods and conditions. We have 
confirmed that SKBR-3, AU 565 and BT-474 over-
express  HER2,30  and  found  that  another  cell  line, 
MDA-MD-435, also over-expresses HER2.
Molecular subtypes, originally identified by gene 
expression  profiling,4–6  were  then  confirmed  by 
IHC analysis.9,10 Numerous studies have shown that 
Luminal A subtype has better differentiated tumors, 
is often seen in older patients and has the best prog-
nosis compared to other subtypes; Luminal B subtype 
has higher expression of proliferation associated genes 
and a worse prognosis than Luminal A; HER2 sub-
type is often associated with nodal metastasis; and 
Basal  subtype  often  occurs  in  younger  patients,  is 
more frequently associated with visceral organ metas-
tasis, and has a poor prognosis.11–13 Since molecular 
Table 3. The results of ihC analysis for all breast caner cell lines.
eR pR HeR2 cK5/6 eGFR Ki-67 AR subtype
MDA-MB-231 0 0 0–1+ − 1+ 100% 8 Basal
sKBR-3 0 0 3+ − 2+ 20% 8 heR2
MDA-MB-231-UR 0 0 0–1+ − 3+ 100% 7 Basal
MCF-12A 0 0 0–1+ + 2+ 95% 5 Basal
hBL101 0 0 0–1+ − 1+ 90% 4 Basal
MDA-MD-435 0 0 3+ − 0 80% 6 heR2
MCF-7 6 6 0–1+ − 1+ 90% 7 Luminal A
hs598T 0 0 0–1+ − 1+ 90% 0 Basal
MCF-10A 0 0 0–1+ + 2+ 30% 0 Basal
BT-20 0 0 0–1+ − 2+ 80% 4 Basal
MCF-10F 0 0 0–1+ + 1+ 100% 0 Basal
468 0 0 0 − 3+ 95% 8 Basal
AU 565 0 0 3+ − 1+ 95% 7 heR2
ZR-75-1 3 4 2+ − 1+ 80% 8 Luminal A
BT-483 0 0 0 − 1+ 95% 4 Basal
BT-474 0 8 3+ − 1+ 70% 7 Luminal B
MDA-MB-453 0 0 0 − 0 80% 8 Unclassfied
note: For eR, PR and AR, Allred scores were used.; for heR2 and egFR the scoring system for heR2 was used; for CK5/6, any strong cytoplasmic stain 
is considered as positive; and for Ki-67, the% of any intensity of nuclear stain was used.
Figure1. Representative staining results from H&E and IHC for ER, PR, HER2, EGFR, CK5/6, Ki-67 and AR (original magnification 400X). A) h & e stain 
for hs 598T cell; B) eR for MCF-7; c) PR for BT-474, D) heR2 for sKBR-3, e) egFR for MDA-MB-231, F) CK5/6 for MCF-10F, G) Ki-67 for MCF-10A, 
and H) AR for ZR-75-1.
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classification has been shown with important clinical 
implications for breast cancer patients, it would be 
important to understand the molecular subtypes of 
commonly used breast cancer cell lines. Most cell 
lines in the current study are Basal subtype, which is 
not surprising, since Basal subtype tumors are more 
aggressive and poorly differentiated, and thus are more 
likely to be established as a cell line compared to better 
differentiated ER positive Luminal subtypes. MDA- 
MB-231 was obtained from MD Anderson Cancer 
Center; and MDA-MB-231 UR was a bone specific 
cell line obtained from University of Rochester (UR, 
a gift from Dr. Guise TA from university of Indiana), 
which may explain the different expression level of 
EGFR. It is important to understand that although 
IHC-based  molecular  classification  has  been  used 
in  numerous  studies,  there  is  still  lack  of  uniform 
definition for each subtype, and the definitive role of 
  molecular classification in guiding clinical decision 
making remains to be confirmed.17
Besides ER, PR and HER2, Ki-67 has become a 
very important predictive and prognostic marker for 
breast  cancer.14,31,32  Using  the  same  conditions  and 
scoring system for IHC analysis used in breast cancer, 
we found most of the cell lines expressed a very high 
level of Ki-67, ranging from 20% to 100%. The very 
aggressive cell line MDA-MB-23133 had 100% cells 
positive for Ki-67, and only two cell lines expressed 
Ki-67  under  50%  (SKBR-3  20%  and  MCF-10A 
30%). One explanation for the dramatic difference 
between cell lines and primary tumors (often under 
50%, with most ranging from 2%–40% in our experi-
ence) is that these tumor cells were harvested at their 
growth phase, while only a very small fraction of pri-
mary tumor cells would be at the growth phase at any 
given time.
Figure 2. examples of the subtypes of molecular classification. A-D) MCF-7 for Luminal A subtype with stains for eR, PR, heR2 and egFR; e-H) BT-474 
for Luminal B subtype with stains for eR, PR, heR2 and egFR; I-L) sKBR-3 for heR2 overexpression subtype with stains for eR, PR, heR2 and egFR; 
M-p) MCF-12A for Basal subtype with stains for eR, PR, heR2 and egFR.
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The results from studies using breast cancer cell 
lines may not be clinically relevant to the general 
breast cancer population. The breast cancer metastasis 
suppressor 1 (BRMS1) is one of a growing number of 
genes that have the ability to suppress metastasis with-
out affecting tumorigenicity in experimental in vivo 
models.34 Transfection of BRM1 into MDA-MB-435 
and MDA-MB-231 has been shown to significantly 
decrease the metastatic potential of both cell lines 
in animal models.35 An examination of BRMS1 in a 
large clinical cohort of breast cancer cases showed 
no correlation between loss of BRMS1 expression by 
IHC and cumulative disease-free survival.36 However 
when stratified by ER negative, PR negative or HER2 
positive  subsets  of  patients,  the  BRMS1-negative 
subgroups had significantly reduced disease-free sur-
vival compared with BRMS1-positive cases.36 Inter-
estingly, the two cell lines used in the initial cell-line 
studies of BRMS1 were both ER, PR negative; and 
MDA-MB-435  was  HER2  positive  in  the  current 
study. These finding highlight the importance of tak-
ing the molecular subtype into consideration when 
attempting to translate findings from breast cancer 
cell lines into a clinical context.
AR has been shown to be an important prognostic 
marker, and associated with better prognosis.37,38 AR 
may also be used as a therapeutic target, especially 
in ER negative breast cancer.39 We have previously 
demonstrated the possible role that AR might play 
during the transition from high grade in situ to inva-
sive ductal carcinoma.40 In the current study, we did 
confirm that MCF-10F is ER negative, but did not 
confirm that it is AR positive, as it has been previ-
ously reported.41
In conclusion, the clinical and biologic heteroge-
neity in breast carcinomas revealed by gene expres-
sion  profiling  is  also  present  among  the  different 
breast cancer cell lines, and can be detected by IHC 
analysis. Attention to these differences should be paid 
when choosing a cell line for any study and attempt-
ing to translate in vitro data into a clinical context.
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